In summary, marked LRRK2 reduction was associated with tumors predicted to have altered distal lung architecture, dysfunctional surfactant metabolism, hyperproliferation and potentially altered innate tumor immunity—in patients who continued to smoke and ultimately suffered worse survival. Here, LRRK2 is linked to neoplasm.